Comparative study of AQP4‑NMOSD, MOGAD and seronegative NMOSD: a single‑center Belgian cohort by Dauby, Solène et al.
Vol.:(0123456789) 
Acta Neurologica Belgica 
https://doi.org/10.1007/s13760-021-01712-3
ORIGINAL ARTICLE
Comparative study of AQP4‑NMOSD, MOGAD and seronegative 
NMOSD: a single‑center Belgian cohort
Solène Dauby1,2  · Dominique Dive1 · Laurence Lutteri4 · Cécile Andris3 · Isabelle Hansen1 · Pierre Maquet1,2  · 
Emilie Lommers1,2 
Received: 31 December 2020 / Accepted: 13 May 2021 
© The Author(s) 2021
Abstract
To emphasize physio-pathological, clinical and prognosis differences between conditions causing serious and sometimes very 
similar clinical manifestations: anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies 
related diseases, and seronegative NMOSD (neuromyelitis optica spectrum disorders).  Based on Wingerchuk et al. (Neu-
rology 85:177–189, 2015) criteria for NMOSD and on those more recently proposed by Jarius et al. (J Neuroinflammation 
15:134, 2018) for MOGAD (MOG associated disorders), we retrospectively surveyed 10 AQP4-NMOSD, 8 MOGAD and 
2 seronegative NMOSD, followed at the specialized neuroimmunology unit of the CHU Liège.  Female predominance was 
only observed in AQP4 group. Age at onset was 37.8 and 27.7 years old for AQP4-NMOSD and MOGAD, respectively. 
In both groups, the first clinical event most often consisted of optic neuritis (ON), followed by isolated myelitis. Fifteen of 
our 20 patients encountered a relapsing course with 90% relapses in AQP4-NMOSD, 62.5% in MOGAD and 50% in the 
seronegative group, and a mean period between the first and second clinical event of 7.1 and 4.8 months for AQP4-NMOSD 
and MOGAD, respectively. In total, we counted 54 ON, with more ON per patient in MOGAD. MOG-associated ON mainly 
affected the anterior part of the optic nerve with a papilledema in 79.2% of cases. Despite a fairly good visual outcome after 
MOG-associated ON, retinal nerve fibre layer (RNFL) thickness decreased, suggesting a fragility of the optic nerve toward 
further attacks. As observed in larger cohorts, our MOGAD and AQP4-NMOSD cases differ by clinical and prognostic fea-
tures. A better understanding of these diseases should encourage prompt biological screening and hasten proper diagnosis 
and treatment.
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Introduction
In 1894, Eugène Devic reported atypical cases of multiple 
sclerosis (MS) characterized by an inflammatory lesion 
of both optic nerves and spinal cord, a condition which 
he dubbed ‘neuromyelitis optica’ (NMO) [1, 2]. NMO 
was considered as a subtype of MS until the discovery 
of causal antibodies against AQP4 protein [3, 4]. This 
objective biomarker allowed for a broadening of NMO 
phenotype to isolated myelitis without optic neuritis (ON) 
or even central nervous system (CNS) involvement with-
out a spinal cord or optic nerve damage, e.g., area pos-
trema syndrome [5]. This pleomorphic phenotype led to 
the concept of ‘NMO spectrum disorders’ (NMOSD) [6]. 
It later appeared that only 80% patients with a NMOSD 
phenotype are seropositive for AQP4-antibodies: other 
cases are seronegative and a minority of them (20%) bear 
antibodies against MOG [7–10]. Initially, MOG-antibodies 
were largely associated to several inflammatory diseases 
including MS, but the former western-blots and ELISA 
lacked specificity. Antibodies against conformational 
MOG epitopes detected by cell-based assay (CBA) were 
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later causally implicated in acute disseminated encepha-
lomyelitis (ADEM) and NMOSD.
The clinical phenotype of disorders with MOG-anti-
bodies far exceeds neuromyelitis optica and includes uni- 
or bilateral, isolated or recurrent ON, myelitis with or 
without ON, ADEM [11], brainstem and supra-tentorial 
lesions [12–14]. These disorders are now referred to as 
‘MOG-associated disorders’ (MOGAD). Finally, patients 
with NMOSD, negative for both AQP4 and MOG anti-
bodies, are now diagnosed as ‘seronegative NMOSD’ 
(SN-NMOSD).
The distinction between MS, AQP4-NMOSD, MOGAD 
and SN-NMOSD is essential but challenging due to over-
lapping clinical, biological and radiological features [8]. A 
reliable diagnosis is mandatory to ensure proper treatment 
and prognosis. Here, we detail the clinical, biological and 
imaging phenotype of AQP4-NMOSD, MOGAD and SN-
NMOSD patients diagnosed in the neuroimmunology unit 
of CHU Liège between 1978 and 2020.
Methods
This monocentric retrospective study is based on the analysis 
of medical records of twenty patients from a local database. 
The cohort consists of 10 AQP4-NMOSD, 8 MOGAD and 
2 SN-NMOSD. Before March 2011, AQP4-antibody detec-
tion was based on indirect immunofluorescence techniques 
on monkey cerebellum slices. From then on, Euroimmun 
CBA was used to test AQP4 locally, and Oxford CBA to test 
MOG in the Multiple Sclerosis and Neuromyelitis Group of 
the Oxford University [15].
Summary statistical analysis consisted of medians and 
percentiles. Non-parametric tests (Kruskal–Wallis and χ2 
tests) were used for group comparisons.
Results
Epidemiological findings
There was a female dominance in AQP4-NMOSD 
(F/M = 10/0; χ2(1) = 20, p < 0.0001), which was not found 
in MOGAD (F/M = 4/4). Age at first clinical event signifi-
cantly varied across groups (Kruskal–Wallis, χ2(2) = 6.77, 
p = 0.033), showing earlier onset in MOGAD patients than in 
AQP4-NMOSD (χ2(1) = 4.18, p = 0.041). Median age at the 
first clinical event was 37.8 years in AQP4-NMOSD (range 
14–73.7) and 27.7 years in MOGAD (range 9.8–39.5). 
The two seronegative patients had their first clinical event, 
respectively, at 63 and 45 years.
Initial clinical event
The initial clinical event in AQP4-NMOSD was unilat-
eral ON (N = 4), myelitis (N = 3), bilateral ON (N = 2), or 
simultaneous myelitis and ON (N = 1). In MOGAD, the ini-
tial clinical event in adults was either a bilateral (N = 4) or 
unilateral (N = 3) ON, or an isolated myelitis (N = 1). In all 
cases, inaugural myelitides were longitudinally extensive 
(≥ 3 vertebral segments) transverse myelitides (LETM) [5]. 
AQP4-NMOSD myelitides were located in the lower cervi-
cal cord and usually expanded to thoracic levels (down to 
T9). The MOGAD LETM affected the upper cervical cord 
with extension to the lower medulla.
Misdiagnosis and delayed diagnosis
The diagnosis of AQP4-NMOSD or MOGAD is demanding 
due to the wide differential diagnosis involving other CNS 
inflammatory conditions. In our 20 patients, the median 
time between the initial clinical event and diagnosis was 
54 months (4.5 years). It is interesting to note that after 
2012 (and the advent of CBA for antibodies testing), median 
time for diagnosis was substantially shorter (7.4 months, 
χ2(1) = 12.18, p = 0.0005; supplemental figure 1). Delayed 
diagnosis did not depend on final diagnosis (χ2(2) = 2.45, 
p = 0.29).
Erroneous initial diagnoses included MS (N = 3), isolated 
or relapsing inflammatory optic neuritis (CRION) (N = 5), 
pseudotumor cerebri (N = 2), ischemic optic neuropa-
thy (N = 1), lupus-related myelitis (N = 1), syringomyelia 
(N = 1), suspected lymphomatous infiltrate (N = 1), iatro-
genic myelitis after anti-TNF alpha treatment (N = 1) [16], 
neurotuberculosis (N = 1) and Harding syndrome (combina-
tion of MS and Leber hereditary optic neuropathy; N = 1). 
None of the MOGAD patients fulfilled the 2017 McDonald 
MS diagnostic criteria [17] whereas 8/10 AQP4-NMOSD 
patients did.
Biological findings
CSF analysis showed lymphocytic pleocytosis in 4/9 AQP4-
NMOSD and in 2/8 MOGAD (χ2(1) = 0.70, p = 0.40) as well 
as CSF oligoclonal bands in 3/10 AQP4-NMOSD (persist-
ing in 2 patients at later CSF control) and no MOGAD 
(χ2(1) = 2.88, p = 0.09).
Half (5/10) of AQP4-NMOSD patients and 2/8 MOGAD 
patients showed biological signs of auto-immunity 
(χ2(1) = 1.17, p = 0.28). Antinuclear antibodies were found 
in all five AQP4-NMOSD patients (4 patients, 1/320; one 
patient 1/640; 1 anti-SSA/Ro, 1 anti-ribosome, 1 anti-
centromere, 2 without characterization). One of them had 
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additional autoantibodies (anti-myeloperoxydase antineu-
trophil cytoplasm antibodies and anti-gastric mucosa). The 
anti-SSA-positive patient was diagnosed with systemic lupus 
erythematosus (SLE). MOGAD patients had either antinu-
clear uncharacterized antibodies (1/160) and psoriasis (1 
patient) or anti-GM1 IgM antibodies, without any clinical 
manifestation (1 patient).
Disease course: monophasic versus relapsing?
The median length of follow-up was 7.5 years with a mini-
mum of 1.4 and a maximum of 32.9 years. Fifteen patients 
suffered at least one relapse (supplemental figure  2). 
Relapses were more prevalent in AQP4-NMOSD than in 
MOGAD: we observed relapses in 9/10 AQP4-NMOSD, 5/8 
MOGAD and 1/2 seronegative patients. However, the dif-
ference in relapse rates between groups was not significant 
(χ2(1) = 0.81, p = 0.67).
First relapse consisted of ON for all MOGAD (5/5) and 
for 5/9 AQP4-NMOSD patients. Two AQP4-NMOSD 
patients relapsed with isolated myelitis and one relapsed 
with simultaneous unilateral ON and myelitis. Relapse 
description is unavailable for the last NMOSD-AQP4 patient 
(Fig. 1). The mean interval between the first and second 
clinical event did not differ between groups: 7.1 months for 
AQP4-NMOSD and 4.8 months for MOGAD (χ2(1) = 0.77, 
p = 0.38).
In AQP4-NMOSD group, several relapses occurred 
despite a first-line immunosuppressive treatment in 6/9, 
leading to therapeutic escalation. By contrast, 2/8 MOGAD 
patients relapsed after treatment initiation. The MOG patient 
M1 relapsed 1.5 months after initiation of mycophenolate 
mofetil (MMF, 1000 mg bid) with a second ON. He was then 
treated by rituximab, which did not prevent 3 additional ON. 
Monthly perfusions of off-label intravenous immunoglobu-
lins (IVIg) stopped relapses for 12 months, so far. Patient 
M6 received MMF (1000 mg bid) after four episodes of 
ON and suffered an additional ON 6 months after treatment 
initiation, probably due to suboptimal treatment adherence.
Seronegative patients
Two female patients fulfilled the Wingerchuk 2015 diag-
nostic criteria for SN-NMOSD [5] (N1, N2, supplemental 
figure 2). AQP4 and MOG antibodies were both tested sev-
eral times, including during clinical relapses, with no avail.
The first patient (N1) had two severe ON, 1 year apart, 
affecting both eyes with complete recovery after intravenous 
Fig. 1  Clinical relapses in 
AQP4 NMOSD group (a) and 
MOGAD group (b). Right-
hand side charts represent the 
proportion of different clinical 
manifestation
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(IV) corticoids. Four years later, she developed dysarthria, 
diplopia and left facial palsy attributable to a ponto-mes-
encephalic inflammatory lesion (Fig. 2). Seven plasma 
exchanges (PLEX) followed by a long-term treatment with 
MMF (1000 mg bid) resulted in an excellent recovery. A 
third relapse, a right hemiparesis, occurred 1 year later, 
due to a left-hemispheric pseudotumoral lesion (Fig. 3). 
Transient improvement was observed after IV corticoids 
and a first rituximab cycle but a new clinical impairment 
associated with lesion growth occurred after 8  weeks. 
Ten PLEX and the continuation of rituximab (one cycle 
every 6 months) resulted in stable clinical and radiological 
improvement. After a 2-year follow-up, the patient is pauci-
symptomatic and no relapse occurred.
The younger patient (N2) suffered a severe bilateral 
asymmetric ON (visual acuity at 1 and 5/10) with cervical 
Fig. 2  Patient 1 (N1) brain MRI. Note the central midbrain lesion with contrast enhancement
Fig. 3  Patient 1 (N1) brain MRI (FLAIR on the left and T1 gadolinium on the right) showing progressive reduction of pseudotumoral lesion size 
and contrast enhancement over time, while receiving rituximab infusions
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myelitis at the age of 45 years. She received 1 g IV corti-
coids for 5 days, followed by six PLEX, two-month treat-
ment by azathioprine, then a single cycle of rituximab (1 g 2 
weeks apart) and a long-term treatment by MMF (1000 mg 
bid). She is currently relapse-free for 3.5 years.
Optic neuritis
Eighteen of our 20 patients had at least one ON. For 16 of 
them, it was the first, and in about half of the cases, the sole 
clinical event. In total, we documented 54 ON (Table 1). 
If we consider the number of ON relapses by a patient, we 
observe more relapses per patient in the MOG group (4.25 
relapses) than in AQP4 group (3 relapses). There was not 
any significant difference in relapse rate between groups, as 
6 AQP4 patients out of 8 had several optic neuritis, for only 
4 MOG patients out of 8 (χ2(2) = 0.61, p = 0.74). The rate of 
bilateral ON was not different between groups (4 bilateral 
ON in both groups for 21 and 22 unilateral ON in AQP4 and 
MOG groups, respectively; χ2(2) = 0.0263, p = 0.99).
The anterior part of the optic nerve was preferentially 
injured in anti-MOG neuritis with 19/25 ON associated with 
papilledema on the fundus examination. By contrast, one 
MOG patient encountered atypical attack of the optic chiasm 
(M2, Fig. 4).
The visual outcome of AQP4-NMOSD encountering ON 
was variable and based on fragmentary information: 3/8 had 
poor (< 1/10) bilateral visual acuity (VA), 2/8 poor unilat-
eral VA, 2/8 moderate (< 8/10) unilateral VA and 1/8 good 
visual outcome.
VA and RNFL thickness courses have been more system-
atically assessed in the 8 MOGAD patients (Fig. 5). VA was 
most of the time well preserved, in contrast to our AQP4-
NMOSD patients. Indeed, all MOGAD patients had VA 
higher or equal to 8.5/10, even after repeated and/or severe 
attacks, except two patients who kept a unilateral VA below 
or equal to 1/10. Figure 5 illustrates the VA and RNFL thick-
ness of MOGAD patients over time while they received cor-
ticoids or PLEX during the acute phase and maintenance 
immunotherapies (azathioprine, MMF, rituximab or IVIg). 
Four out of 8 MOG-patients (Table 1) encountered only one 
ON and did not relapse under immunotherapy: M2, M3, M5 
and M8 of Fig. 5.
Among the 4 MOG-patients who experienced at least one 
ON relapse: M1 patient relapsed under MMF, leading to 
therapeutic escalation by rituximab and then by IVIg. M4 
patient only received azathioprine after 6 ON event but it did 
not prevent the seventh one, leading to methotrexate and then 
rituximab introduction. As mentioned above, M6 patient 
relapsed under MMF treatment because of a suboptimal 
Table 1  Optic neuritis (ON) and 
relapses in each group
AQP4 MOG Seronegative Total
Patients with ≥ 1 ON 8/10 (80%) 8/8 (100%) 2/2 (100%) 18/20 (90%)
Total number of ON 26 25 3 54
 Unilateral ON 22 (84.6%) 21 (84%) 2 (66.7%) 45
 Bilateral ON 4 (15.4%) 4 (16%) 1 (33.3%) 9
Patients with ≥ 1 relapse of ON 6/8 (75%) 4/8 (50%) 1/2 (50%) 11/18 (61.1%)
Average number of relapse if relapse(s) 3 4.25 1 –
Fig. 4  Brain MRI showing a 
lesion of the optic chiasm in a 
MOGAD patient (M2), with 
contrast enhancement
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treatment adherence. Finally, M7 patient received MMF 
after 3 ON and no relapse has happened since then.
Discussion
Neurological syndromes associated with MOG- and AQP4-
antibodies now appear as two separate demyelinating dis-
eases, characterized by distinct pathophysiology: AQP4-
NMOSD is an astrocytopathy while MOGAD currently 
appears as an oligodendrogliopathy [18]. Although they may 
share similar clinical phenotype, epidemiological and clini-
cal specificities were previously described in larger cohorts.
In keeping with the literature [8, 11, 18–26], gender and 
age at onset were significantly different between groups with 
a clear female prevalence in AQP4-NMOSD and a younger 
age of onset in MOGAD. Co-existing auto-antibodies were 
observed in both groups, but more frequently with AQP4-
NMOSD than with MOGAD as reported in the literature 
[27–30]. Seropositivity for autoantibodies, mainly antinu-
clear, can reach 38 to 75% in NMOSD patients whether 
AQP4 positive or seronegative [28]. SLE and Sjögren syn-
drome are the most prevalent associated autoimmune dis-
eases in AQP4-NMOSD, followed by myasthenia gravis and 
thyroiditis. The reasons explaining the differential propor-
tion of autoimmune comorbidities between AQP4-NMOSD 
and MOGAD remain unclear: whereas AQP4-NMOSD 
results from abnormal B-cell tolerance checkpoint, MOGAD 
would rather be due to molecular mimicry [30].
The initial clinical event in AQP4-NMOSD is, by decreas-
ing frequency, unilateral ON, myelitis, bilateral ON, myelitis 
plus ON, brainstem (mainly an area postrema syndrome) 
Fig. 5  Charts on the left-hand side represent visual acuity of both 
eyes over time for each MOGAD patients and charts on the right-
hand side represent RNFL thickness measured by OCT over time. 
RNFL thickness is clearly reduced for optic nerves that were injured 
by inflammation, and this slimming is obvious even when visual acu-
ity shows a good recovery. This is particularly the case for patients 
M3, M4 and M7 whose visual acuities are bilaterally assessed at 
10/10 by the end of follow-up but whose optic nerve thickness are 
distinctly altered
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and supra-tentorial lesions [5, 31]. In MOGAD, the first 
clinical event depends on the age of onset [22]. ADEM and 
encephalopathy predominate in the paediatric population 
while adults are more likely to suffer from myelitis or ON. 
Brainstem, cerebral parenchyma or cerebellar attacks as well 
as multifocal lesions have also been described [22, 23, 32]. 
ON was the most represented first clinical event in our entire 
cohort (more often bilateral in anti-MOG than anti-AQP4 in 
larger cohorts than ours [12, 33]), followed by myelitis and 
the simultaneous attack of both regions. This is consistent 
with earlier studies [24, 26, 33–35]. We noted the conspicu-
ous absence of ADEM in our cohort, which only included 
two children under the age of 16. Moreover, adult forms of 
ADEM are less frequently associated with anti-MOG sero-
positivity [36].
ON was the most common manifestation for both condi-
tions. Compared to typical MS and idiopathic ON, optic 
nerve attacks in AQP4-NMOSD and MOGAD are more 
severe, more often bilateral, extensive and associated with 
perineural enhancement [11, 37, 38]. Antibodies testing 
must therefore be considered in all cases of atypical ON. 
Beside biological clues, the lesion topography, as assessed 
by ophthalmological examination and magnetic resonance 
imaging, also helps distinguishing AQP4-NMOSD from 
MOGAD associated ON. Anterior part of the optic nerve 
is preferentially injured in anti-MOG neuritis, whereas in 
AQP4-neuritis, it rather concerns the posterior part of the 
visual pathways [37, 39]. Fundus examination sometimes 
shows papillitis or papilledema suggestive of an anterior 
neuritis. However, this finding might not be sensitive enough 
for the detection of a slight papilledema, for which an optical 
coherence tomography (OCT) is needed. Papilledema was 
observed in 85% of MOG-associated ON described in the 
literature [40] and in 79.2% of our cases (19/25). This find-
ing can be misleading and suggest pseudotumor cerebri—
for bilateral attack—or an anterior ischemic optic neuropa-
thy—for unilateral attack, as it was the case for some of our 
patients. It however should be kept in mind that posterior 
Fig. 5  (continued)
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and even chiasmatic attack may occur in 5–15% of MOG-
associated ON [23, 37, 38, 41, 42], as in patient M2 (Fig. 4).
Existing literature indicates that ON relapse more fre-
quently in MOGAD than in AQP4-NMOSD [11, 35]. This 
trend was not observed in our cohort, as 75% of our AQP4 
patients (6/8) have undergone several ON, for only 50% 
in the MOG group (4/8). However, within patients who 
relapsed, the number of ON relapses per patient was higher 
in the MOG group (4.25 relapses) than in the AQP4 group (3 
relapses). The rate of bilateral attacks was not significantly 
different between groups.
Functional prognosis remains good in the MOG group: 
follow-up typically showed a good VA recovery after anti-
MOG neuritis, in keeping with previous studies [11, 24, 
25, 33, 39, 40, 43, 44]. Nevertheless, the progressive and 
irreversible atrophy of the optic nerve, as measured by the 
RNFL thickness with OCT, is a compelling argument to treat 
patients as early as possible. Concordant with the literature, 
our sample of AQP4-NMOSD patients showed a worse vis-
ual outcome. However, delayed diagnosis and treatment as 
compared to MOG patients (supplemental figure 2) can in 
part explain this result.
AQP4-NMOSD and MOGAD usually follow a relapsing 
course but, in contrast to MS, do not show any significant 
progression [8, 45]. Most of our patients (15/20) suffered 
clinical relapses, with no significant difference in relapse 
rates or interval between the first and second event between 
our two groups. By contrast, the literature indicates a relapse 
rate lower in MOGAD than in AQP4-NMOSD, and related 
to MOG antibodies titre [23, 24]. Antibody levels increase 
during disease activity but decrease (and can become unde-
tectable) between relapses as well as under immunosup-
pressive treatment [19, 23, 24]. Based on this observation, 
treatment was discontinued in two patients (M3, M5) after 
they turned out to be seronegative for MOG-antibody. They 
did not relapse so far for two and one year and a half, respec-
tively. As suggested in Ref. [46], antibody titres are moni-
tored every 6 or 12 months and are still undetectable.
Two patients in our cohort were seronegative for both 
AQP4 and MOG antibodies and fulfilled diagnostic criteria 
for SN-NMOSD [5]. They encountered a favourable out-
come with good clinical recovery after prompt and appropri-
ate treatment. While SN-NMOSD are more likely monopha-
sic diseases and associated with less severe clinical attack 
[31], N1 seronegative patient experienced 3 severe relapses, 
including a vast pseudotumoral lesion of the left sensorimo-
tor cortex (Fig. 3).
Before the advent of CBA for antibodies testing in 2012, 
the diagnosis of NMOSD or MOGAD was challenging due 
to a large number of alternative diagnoses. In our entire 
cohort, the median time between initial clinical event and 
diagnosis was 54 months (4.5 years), with a substantial 
reduction of this period (7.4 months) when considering 
patients whose first clinical event occurred after 2012. This 
finding emphasizes the diagnostic advance provided by CBA 
testing.
From our experience, earlier diagnosis led to prompt 
treatment and better clinical outcome. Because MOGAD 
and AQP4-NMOSD are relapsing conditions, a preventive 
immunosuppressive treatment must always be considered 
at the time of diagnosis. Moreover, the importance of an 
accurate differential diagnosis between MOGAD and AQP4-
NMOSD is becoming crucial. While acute management con-
sists of intravenous high doses of corticosteroids and PLEX 
(especially for refractory conditions) for both diseases, 
chronic treatment should differ. Monoclonal anti-CD20 
rituximab seems considerably more efficient in AQP4-
NMOSD than in MOGAD, with 80–90% response instead 
of ~ 30%, respectively [47, 48]. Eculizumab, inebilizumab 
and satralizumab in AQP4-NMOSD seem associated with 
good outcomes [49, 50]. Interleukin 6 pathway inhibitors 
or complement blocking therapies have been tried in some 
MOGAD patients [51] but dedicated clinical trials are not 
available yet. For this condition, no standardized therapy 
is recommended. Recent publications suggest that IVIg 
should be considered in MOGAD while a positive effect 
was observed in one paediatric series [52, 53]. Four of our 
MOGAD patients were only treated by MMF (M3, 5, 6, 7), 
two received directly rituximab (M2, 8) and one received 
rituximab after azathioprine and methotrexate (M4). The 
last one was first treated by MMF but required a therapeutic 
escalation with rituximab then IVIg (M1).
Conclusion
This retrospective analysis confirms that AQP4-NMOSD 
and MOGAD do not only differ by aetiology, but also 
by some clinical features and prognosis. As compared to 
MOGAD, AQP4-NMOSD is typically more frequent in 
females, occurs at an older age, involves the posterior optic 
nerve and relapses more frequently.
Practitioners should not hesitate to resort to ophthal-
mological assessment and to relevant biological screening 
in suggestive cases for promptly orienting the diagnosis, 
thereby avoiding severe disability observed during the natu-
ral course of these diseases.
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